This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBabylon Holdings（BBLN.F）株式概要Babylon Holdings Limited operates as a digital healthcare company. 詳細BBLN.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6リスク分析マイナスの株主資本 US市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去1年間で株主の希薄化は大幅に進んだ 過去5年間で収益は年間12.9%減少しました。 +1 さらなるリスクすべてのリスクチェックを見るBBLN.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.02199.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-256m1b2016201920222025202620282031Revenue US$1.2bEarnings US$134.2mAdvancedSet Fair ValueView all narrativesBabylon Holdings Limited 競合他社InnovaQorSymbol: OTCPK:INQRMarket cap: US$204.0SCWorxSymbol: OTCPK:WORXMarket cap: US$320.1kiSpecimenSymbol: NasdaqCM:ISPCMarket cap: US$4.1mAclarionSymbol: NasdaqCM:ACONMarket cap: US$7.2m価格と性能株価の高値、安値、推移の概要Babylon Holdings過去の株価現在の株価US$0.02152週高値US$24.0052週安値US$0.01ベータ1.731ヶ月の変化-73.71%3ヶ月変化-98.24%1年変化-99.90%3年間の変化n/a5年間の変化n/aIPOからの変化-99.99%最新ニュースお知らせ • Jun 29Babylon Announces the Receipt of Continued Listing Standards Notice from NYSE and Upcoming DelistingBabylon Holdings Limited announced that on June 22, 2023, the Company received a notice from the New York Stock Exchange indicating the Company is not in compliance with Section 802.01B and Section 802.01C of the NYSE Listed Company Manual because (i) the Company’s average total market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its last reported shareholders’ equity was less than $50 million, and (ii) the average closing price of the Company’s Class A ordinary shares on the NYSE was less than $1.00 over a consecutive 30 trading-day period. In light of the expected closing of the Proposed Transaction in July 2023, the Company does not intend to undertake actions to cure the deficiencies described above and return to compliance with the NYSE continued listing standards, and has notified the NYSE of this decision. As a result, the Company expects the NYSE to immediately suspend its Class A ordinary shares from trading on the NYSE under the ticker symbol “BBLN”, and for the Class A ordinary shares to transition to trading on the over-the-counter market. In addition, the Company expects the NYSE to subsequently delist the Class A ordinary shares from the NYSE in accordance with its procedures. The Company will continue to comply with applicable Securities and Exchange Commission reporting requirements. The Notice and the expected suspension of trading and subsequent delisting of the Class A ordinary shares from the NYSE do not affect the business operations of the Company and its subsidiaries, and will have no impact on the Proposed Transaction.お知らせ • May 26Babylon Holdings Limited Announces Board ChangesOn May 24, 2023, Per Brilioth and Georgi Ganev notified the board of directors of Babylon Holdings Limited of their respective resignations as directors, effective immediately. The respective decisions of Messrs. Brilioth and Ganev were not the result of any dispute or disagreement with the Company on any matter relating to the Company’s operations, policies or practices. On May 19, 2023, the Board appointed Aidan de Brunner to the Board and the Audit, Nominating and Corporate Governance, Remuneration, and Strategic Committees of the Board, effective as of May 19, 2023. The Board has determined that Mr. de Brunner is independent under the standards of the Securities and Exchange Commission and the New York Stock Exchange, and meets the additional standards applicable to members of the Audit Committee. Mr. de Brunner was nominated by the Majority Bridge Noteholders pursuant to the bridge loan notes facility agreement, dated March 9, 2023, among the Company, as borrower, Babylon Healthcare Inc., Babylon Partners Ltd., Babylon Inc., and Babylon Group Holdings Limited, as guarantors, and Kroll Trustee Services Limited, as trustee and security agent, as amended and restated by the amendment and restatement agreement, dated May 10, 2023 (as so amended and restated, the "Amended Bridge Facility Agreement"). Mr. Eugene I. Davis, who was appointed to the Board effective as of March 30, 2023, and Mr. de Brunner are the two Bridge Noteholder-selected Independent Directors. If Mr. de Brunner resigns from the Board, the Majority Bridge Noteholders may nominate a replacement Bridge Noteholder-selected Independent Director, and the Company has agreed to use all reasonable endeavors to effect the appointment of such replacement Bridge Noteholder-selected Independent Director within the time period specified in the Amended Bridge Facility Agreement.お知らせ • May 11Babylon Holdings Limited Announces Withdrawn Earnings Guidance for the Year 2023Babylon Holdings Limited announced withdrawn earnings guidance for the year 2023. In light of the company’s announcement concerning an interim financing and proposed take private transaction to be led by AlbaCore Capital LLP and affiliates, the company has withdrawn its full-year 2023 revenue guidance issued on March 9, 2023. The company is not providing updated guidance at this time.Reported Earnings • May 11First quarter 2023 earnings released: US$2.53 loss per share (vs US$5.94 loss in 1Q 2022)First quarter 2023 results: US$2.53 loss per share (improved from US$5.94 loss in 1Q 2022). Revenue: US$311.1m (up 17% from 1Q 2022). Net loss: US$63.2m (loss narrowed 31% from 1Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in the US.Recent Insider Transactions • Mar 22Global Chief Medical Officer recently sold US$74k worth of stockOn the 15th of March, Darshak Sanghavi sold around 10k shares on-market at roughly US$7.71 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Recent Insider Transactions • Mar 17Global Chief Medical Officer recently sold US$74k worth of stockOn the 15th of March, Darshak Sanghavi sold around 10k shares on-market at roughly US$7.74 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.最新情報をもっと見るRecent updatesお知らせ • Jun 29Babylon Announces the Receipt of Continued Listing Standards Notice from NYSE and Upcoming DelistingBabylon Holdings Limited announced that on June 22, 2023, the Company received a notice from the New York Stock Exchange indicating the Company is not in compliance with Section 802.01B and Section 802.01C of the NYSE Listed Company Manual because (i) the Company’s average total market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its last reported shareholders’ equity was less than $50 million, and (ii) the average closing price of the Company’s Class A ordinary shares on the NYSE was less than $1.00 over a consecutive 30 trading-day period. In light of the expected closing of the Proposed Transaction in July 2023, the Company does not intend to undertake actions to cure the deficiencies described above and return to compliance with the NYSE continued listing standards, and has notified the NYSE of this decision. As a result, the Company expects the NYSE to immediately suspend its Class A ordinary shares from trading on the NYSE under the ticker symbol “BBLN”, and for the Class A ordinary shares to transition to trading on the over-the-counter market. In addition, the Company expects the NYSE to subsequently delist the Class A ordinary shares from the NYSE in accordance with its procedures. The Company will continue to comply with applicable Securities and Exchange Commission reporting requirements. The Notice and the expected suspension of trading and subsequent delisting of the Class A ordinary shares from the NYSE do not affect the business operations of the Company and its subsidiaries, and will have no impact on the Proposed Transaction.お知らせ • May 26Babylon Holdings Limited Announces Board ChangesOn May 24, 2023, Per Brilioth and Georgi Ganev notified the board of directors of Babylon Holdings Limited of their respective resignations as directors, effective immediately. The respective decisions of Messrs. Brilioth and Ganev were not the result of any dispute or disagreement with the Company on any matter relating to the Company’s operations, policies or practices. On May 19, 2023, the Board appointed Aidan de Brunner to the Board and the Audit, Nominating and Corporate Governance, Remuneration, and Strategic Committees of the Board, effective as of May 19, 2023. The Board has determined that Mr. de Brunner is independent under the standards of the Securities and Exchange Commission and the New York Stock Exchange, and meets the additional standards applicable to members of the Audit Committee. Mr. de Brunner was nominated by the Majority Bridge Noteholders pursuant to the bridge loan notes facility agreement, dated March 9, 2023, among the Company, as borrower, Babylon Healthcare Inc., Babylon Partners Ltd., Babylon Inc., and Babylon Group Holdings Limited, as guarantors, and Kroll Trustee Services Limited, as trustee and security agent, as amended and restated by the amendment and restatement agreement, dated May 10, 2023 (as so amended and restated, the "Amended Bridge Facility Agreement"). Mr. Eugene I. Davis, who was appointed to the Board effective as of March 30, 2023, and Mr. de Brunner are the two Bridge Noteholder-selected Independent Directors. If Mr. de Brunner resigns from the Board, the Majority Bridge Noteholders may nominate a replacement Bridge Noteholder-selected Independent Director, and the Company has agreed to use all reasonable endeavors to effect the appointment of such replacement Bridge Noteholder-selected Independent Director within the time period specified in the Amended Bridge Facility Agreement.お知らせ • May 11Babylon Holdings Limited Announces Withdrawn Earnings Guidance for the Year 2023Babylon Holdings Limited announced withdrawn earnings guidance for the year 2023. In light of the company’s announcement concerning an interim financing and proposed take private transaction to be led by AlbaCore Capital LLP and affiliates, the company has withdrawn its full-year 2023 revenue guidance issued on March 9, 2023. The company is not providing updated guidance at this time.Reported Earnings • May 11First quarter 2023 earnings released: US$2.53 loss per share (vs US$5.94 loss in 1Q 2022)First quarter 2023 results: US$2.53 loss per share (improved from US$5.94 loss in 1Q 2022). Revenue: US$311.1m (up 17% from 1Q 2022). Net loss: US$63.2m (loss narrowed 31% from 1Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in the US.Recent Insider Transactions • Mar 22Global Chief Medical Officer recently sold US$74k worth of stockOn the 15th of March, Darshak Sanghavi sold around 10k shares on-market at roughly US$7.71 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Recent Insider Transactions • Mar 17Global Chief Medical Officer recently sold US$74k worth of stockOn the 15th of March, Darshak Sanghavi sold around 10k shares on-market at roughly US$7.74 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Major Estimate Revision • Mar 16Consensus revenue estimates decrease by 16%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$1.44b to US$1.21b. EPS estimate increased from -US$14.34 to -US$9.33 per share. Healthcare Services industry in the US expected to see average net income growth of 1.0% next year. Consensus price target down from US$16.25 to US$14.15. Share price fell 31% to US$6.86 over the past week.Reported Earnings • Mar 10Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: US$8.91 loss per share (improved from US$33.95 loss in FY 2021). Revenue: US$1.11b (up 244% from FY 2021). Net loss: US$221.4m (loss narrowed 40% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 50%. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare Services industry in the US.お知らせ • Feb 17Babylon Holdings Limited to Report Q4, 2022 Results on Mar 09, 2023Babylon Holdings Limited announced that they will report Q4, 2022 results on Mar 09, 2023お知らせ • Jan 13Babylon Holdings Limited Provides Unaudited Earnings Guidance for the Year Ended December 31, 2022Babylon Holdings Limited provided unaudited earnings guidance for the year ended December 31, 2022. For the period, the company is expected to exceed $1.05 billion on both a U.S. GAAP and International Financial Reporting Standards (IFRS) basis, including revenue from the IPA business in California.Major Estimate Revision • Nov 17Consensus estimates of losses per share improve by 10%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from US$1.08b to US$1.10b. EPS estimate increased from -US$1.13 per share to -US$1.01 per share. Healthcare Services industry in the US expected to see average net income growth of 12% next year. Consensus price target down from US$2.74 to US$2.10. Share price rose 17% to US$0.53 over the past week.Price Target Changed • Nov 16Price target decreased to US$2.10Down from US$2.74, the current price target is an average from 7 analysts. New target price is 283% above last closing price of US$0.55. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$1.01 next year compared to a net loss per share of US$1.36 last year.Board Change • Nov 16High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 1 experienced director. 1 highly experienced director. Founder, Chairman & CEO Parsa Parsadoust is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 11Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.23 loss per share (further deteriorated from US$0.08 loss in 3Q 2021). Revenue: US$288.9m (up 288% from 3Q 2021). Net loss: US$89.9m (loss widened 38% from 3Q 2021). Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 5.8%. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare Services industry in the US.お知らせ • Nov 11+ 1 more updateVNV (Cyprus) Limited Engages in Discussions with Babylon Holdings LimitedOn November 10, 2022, VNV (Cyprus) Limited announced that it and its respective representatives have engaged and/or may engage, from time to time, in discussions with Babylon Holdings Limited’s management and/or board of directors, including any special committees of the Board, and/or their respective advisors, regarding, among other things, the Company’s business, strategies, management, governance, operations, personnel, performance, financial matters, capital structure, corporate expenses, status of projects, hedging, environmental, health and safety matters and strategic and other transactions, and have engaged and/or intend to, from time to time, engage in discussions with other current or prospective holders of Class A Shares and/or other equity, debt, notes, instruments or securities, or rights convertible into or exchangeable or exercisable for Class A Shares or such other equity, debt, notes, instruments or securities, of the Company industry analysts, research analysts, rating agencies, existing or potential strategic partners of the Company, acquirers or competitors, financial sponsors, investment firms, investment professionals, capital and potential capital sources, operators, financial, and other consultants and advisors and other third parties regarding such matters.Seeking Alpha • Nov 09Babylon to execute 1-for-25 reverse share splitBabylon (NYSE:BBLN) is implementing a 1-for-25 reverse share split of its Class A ordinary shares in a bid to increase the per share trading price to regain compliance with NYSE's minimum share price requirement. The split will become effective on Dec 15, 2022 and the Class A ordinary shares will begin trading on a split-adjusted basis on Dec 16, 2022. Concurrent with the move, the par value of the Class A ordinary shares will be changed to $0.0001 per share. The number of issued and outstanding shares will be reduced from ~620M to ~24.8M shares.お知らせ • Nov 05Babylon Holdings Limited announced that it has received $80 million in funding from VNV Global AB (publ), Kinnevik AB and other investorsOn November 3, 2022, Babylon Holdings Limited closed the transaction.お知らせ • Oct 19Babylon Holdings Limited announced that it expects to receive $61.45 million in funding from VNV Global AB (publ), Kinnevik AB and other investorsBabylon Holdings Limited announced that it has agreed to sell an aggregate of 145,885,760 Class A ordinary shares at a price of $0.42122 per share for gross proceeds of $61,450,000 on October 17, 2022. The transaction will include participation from certain institutional, other accredited investors, and entities affiliated with returning investors VNV Global AB, Kinnevik AB. The closing of the PIPE is expected to occur on or about November 3, 2022. The securities to be sold in the PIPE are being offered in a transaction not involving a public offering, have not been registered under the Securities Act of 1933, as amended and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.お知らせ • Oct 18Babylon Holdings Limited Announces Resignation of Yon Nuta as Chief Product Officer, Effective October 18, 2022Babylon Holdings Limited announced Yon Nuta has resigned from his position as chief product officer of the company, effective October 18, 2022. Mr. Nuta’s responsibilities are being transitioned to Aron England, the company’s Vice President of Product, who joined Babylon in August 2021 and leads the company’s product platform organization.Seeking Alpha • Oct 17Babylon Holdings files to sell 145.89M Class A ordinary sharesBabylon (NYSE:BBLN) has agreed to sell an aggregate of 145.89M of its Class A ordinary shares to certain institutional and other accredited investors in a private investment in public equity at a price of $0.42122/share. Babylon anticipates that the gross proceeds from the Initial Subscriptions will be $61.45M, before deducting offering expenses payable by the Co. Babylon expects to use the proceeds from the PIPE to fund the ongoing development of its digital-first platform and services for managing population health, working capital and other general corporate purposes. The closing of the PIPE is expected to occur on or about November 3, 2022.お知らせ • Oct 14Babylon Holdings Limited to Report Q3, 2022 Results on Nov 10, 2022Babylon Holdings Limited announced that they will report Q3, 2022 results on Nov 10, 2022お知らせ • Oct 13Babylon Holdings Reportedly to Sell Meritage IPA Assets in Early 2023Babylon Holdings Limited (NYSE:BBLN) to sell Meritage IPA assets in early 2023 - Babylon intends to divest Meritage Medical Network. Proceeds from the sale are expected to provide sufficient capital for Babylon's funding requirements through profitability.お知らせ • Sep 29Babylon Hires Andrew Hine as Vice President of the Europe, Middle East, & Africa & Asia Go-To-Market TeamBabylon announced the hiring of Andrew Hine as Vice President of the Go-to-Market team. Hine joins Babylon’s Go-to-Market leadership team from Ernst & Young. In this role, Hine will lead the company’s sales efforts in Asia and EMEA and he will work closely with Paul-Henri Ferrand, Babylon’s Chief Operating Officer (COO), to oversee the execution of Babylon’s overseas expansion. As Babylon continues to strengthen its capabilities and enhance its presence in new and existing markets, Hine will lead the company’s growing network of contracts, collaborations, and partnerships, as well as increase the scale of Babylon’s service delivery and offerings. Hine's extensive healthcare background spans 30 years, 13 of which were spent as an NHS Operational Manager and Trust Board Director. He has led service delivery at the frontline in tertiary and secondary acute care, primary care, and mental health care services. Following his tenure with the NHS, Hine joined KPMG where he established and led its UK healthcare business as a consulting partner for 13 years, leading client engagements across the UK, Europe and the Middle East, particularly focusing on the strategic design, operational improvement and leadership of health services, organizations and systems. After KPMG, Hine joined Ernst & Young as the company’s Head of Health for the Middle East and North Africa. He spent the last four years working extensively across Saudi Arabia, Qatar, and the United Arab Emirates.お知らせ • Sep 23Babylon Receives Share Price Notice from the New York Stock Exchange Due to Non-Compliance with NYSE Rule 802.01CBabylon Holdings Limited announced that on September 15, 2022, it received notice from the New York Stock Exchange (the “NYSE”) that it is not in compliance with NYSE Rule 802.01C of the NYSE Listed Company Manual that requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period (the “Notice”). Babylon has notified the NYSE of its intent to cure this deficiency, within six months following the receipt of the Notice in accordance with the NYSE’s rules, by implementing a reverse share split. At Babylon’s Annual General Meeting of Shareholders on September 14, 2022, Babylon received shareholder approval of a reverse share split at a consolidation ratio of between 15 and 25. After Babylon’s Board of Directors approves the consolidation ratio to be applied, Babylon intends to move ahead with the implementation of the reverse share split as soon as possible in the fourth quarter of 2022. After effecting the reverse share split, the deficiency will be deemed cured if the closing price of the Class A ordinary shares promptly exceeds $1.00 per share, and the price remains above that level for at least the following 30 trading days.Seeking Alpha • Sep 22Babylon receives NYSE notice and gets approval for reverse share split at a consolidation ratio of between 15 and 25Babylon (NYSE:BBLN) received notice from the NYSE that it is not in compliance with listings standards as it did not maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period. Company received shareholder approval of a reverse share split at a consolidation ratio of between 15 and 25, which is intended as soon as possible in Q4 2022. Company believes that a reverse share split will also benefit its shareholders because it will enable to reach additional institutional shareholders who impose minimum price requirements.お知らせ • Aug 24Babylon Holdings Limited Announces Chief Financial Officer ChangesBabylon Holdings Limited announced that David Humphreys will be appointed as the Company’s new Chief Financial Officer. Mr. Humphreys has been at Babylon for nearly two years in the role of Finance Director, with overall responsibility for building and scaling Babylon’s finance function. Formerly, he was US-based as a Silicon Valley and New York Partner with PwC for over 20 years, working with Boards and leaders of fast-moving, rapid-growth companies including Tesla and Facebook to which he provided accounting consulting, transaction, IPO, M&A and auditing services to ensure compliance with PCAOB and SEC reporting requirements. During his time with PwC, Mr. Humphreys also served as a Practice Fellow at the International Accounting Standards Board, and is both a U.S. Certified Public Accountant (CPA) and an ICAEW Fellow Chartered Accountant. Current Chief Financial Officer, Charlie Steel, will leave his position to pursue another opportunity. Mr. Steel will remain at Babylon for a period to ensure the effective transition of his responsibilities to Mr. Humphreys.Seeking Alpha • Aug 23Babylon gets new CFOBabylon (NYSE:BBLN) announces that David Humphreys will be appointed as new CFO. Mr. Humphreys has been at Babylon for nearly two years in the role of Finance Director, with overall responsibility for building and scaling company’s finance function. Current CFO, Charlie Steel, will leave his position to pursue another opportunity; Mr. Steel will remain at the compny for a period to ensure the effective transition of his responsibilities to Mr. Humphreys.お知らせ • Aug 16Babylon Holdings Denies Acquisition RumorsBabylon Holdings Limited (NYSE:BBLN) announced that it is not engaged in nor has it had contact or discussions with any potential acquirer. The company is actively working with the staff of the NYSE to resume trading as soon as possible.Seeking Alpha • Aug 15Babylon Holdings jumps after report of potential sale processBabylon Holdings (NYSE:BBLN) soared 9.2% after a report that the U.K.-based digital healthcare company is said to be consider a take private transaction. Babylon, which connects patients and doctors via an apps, is said to be holding early talks with investors about how to address its sinking share price, according to traders, who cited a Bloomberg report. BBLN shares have plunged 92% since going public through a SPAC transaction in October. The company is looking at options including a take private to a possible deal with a strategic partner, according to the report. Babylon (BBLN) could also look to raise new funds to grow its business. Babylon (BBLN) originally announced a deal to go public through SPAC Alkuri Global Acquisition in June of last year, which was expected to value the combined company at an equity value of about $4.2 billion. Babylon currently has a market value of about $287 million. Last Tuesday Babylon (BBLN) reported Q2 GAAP EPS of -$0.41, revenue of $265.36M.Reported Earnings • Aug 11Second quarter 2022 earnings: EPS misses analyst expectationsSecond quarter 2022 results: US$0.41 loss per share (down from US$0.26 loss in 2Q 2021). Revenue: US$265.4m (up 362% from 2Q 2021). Net loss: US$157.1m (loss widened 144% from 2Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 54%. Over the next year, revenue is forecast to grow 81%, compared to a 19% growth forecast for the industry in the US.お知らせ • Aug 10Babylon Holdings Limited Provides Guidance for the Twelve Months Ending December 31, 2022Babylon Holdings Limited providing guidance For the twelve months ending December 31, 2022, company is reiterating its revenue guidance of $1.0 billion or greater, which represents a more than 3x increase over 2021 revenue driven predominantly by organic growth, fueled by state expansion in the U.S. with existing clients, as well as members from new clients.お知らせ • Aug 02Babylon Holdings Limited Announces Executive ChangesBabylon Holdings Limited announced that Paul-Henri Ferrand. Mr. Ferrand, formerly the Chief Business Officer of Babylon Holdings Limited (“Babylon”), has been appointed as Babylon’s Chief Operating Officer effective immediately. In this expanded role, Mr. Ferrand will continue to lead Babylon’s Go-to-Market teams, but will also lead Babylon’s wider business operations, including strategic and operational planning. Mr. Ferrand joined Babylon in October 2020. Prior to joining Babylon, Mr. Ferrand served as Chief Operating Officer at Brex, a financial services company, from November 2019 to September 2020. Previously, Mr. Ferrand served as President of Global Customer Operations at Google, from August 2017 to June 2019, and as Vice President US Sales & Operations at Google from May 2014 to August 2017. Steve Davis. Mr. Davis has resigned from his position as Chief Technology Officer, effective August 12, 2022. Mr. Davis’s responsibilities are being transitioned to Praveen Hirsave, Babylon’s Vice President of Engineering, who currently oversees Babylon’s member and artificial intelligence platform strategies. Babylon wishes Steve well in the future. Darshak Sanghavi. Effective immediately, Mr. Sanghavi’s role as Babylon’s Chief Medical Officer has been expanded to include oversight of Babylon’s clinical organizations. In this expanded role, Mr. Sanghavi’s additional responsibilities will include partnering with the regional general managers of Babylon’s clinical operations to ensure that Babylon’s technology and services create direct value to the improvement of contract margins and the engagement of Babylon’s members. Mr. Sanghavi joined Babylon in May 2021. Prior to joining Babylon, Mr. Sanghavi served as Chief Medical Officer at UnitedHealthcare, a provider of health benefits programs in the United States, from August 2019 to August 2020. Previously, Mr. Sanghavi served as Chief Medical Officer at OptumLabs, a pharmacy benefit manager and part of UnitedHealth Group Incorporated, from August 2016 to August 2019, and in the Obama Administration as the Director of Preventative and Population Health at the Center for Medicare and Medicaid Innovation from August 2014 to September 2016. Mr. Sanghavi is also an Associate Professor of Pediatrics and served as Chief of Pediatric Cardiology at the University of Massachusetts Medical School from October 2005 to August 2014.お知らせ • Jul 29Babylon Holdings Limited, Annual General Meeting, Sep 14, 2022Babylon Holdings Limited, Annual General Meeting, Sep 14, 2022, at 09:00 Central Standard Time. Agenda: To consider Retirement and re-election of directors; To re-appoint KPMG LLP in the United Kingdom as auditors of the Company to hold office from the conclusion of the AGM ; to consider To approve the Reverse Share Split ; and to consider other matters.お知らせ • Jul 13Babylon Holdings Limited to Report Q2, 2022 Results on Aug 09, 2022Babylon Holdings Limited announced that they will report Q2, 2022 results Pre-Market on Aug 09, 2022お知らせ • Jul 07Babylon Holdings Limited Provides Earnings Guidance for the Year 2022Babylon Holdings Limited provided earnings guidance for the year 2022. For the year, the company expects there is no change to Babylon's revenue guidance being $1.0 billion or greater for Fiscal Year 2022.Seeking Alpha • Jul 06Babylon +2%, expects $100M savings per yearBabylon (NYSE:BBLN) plans to accelerate its path to profitability through revenue and cost efficiencies, implemented in Q3 and expects effect in Q4. Company is improving its Adjusted EBITDA guidance for FY 2022 from $(295)M or less to $(270)M or less, with forecasted monthly December 2022. Adjusted EBITDA of $(18)M or less. No change to Babylon's revenue guidance being $1B or greater for FY 2022. Expects to generate savings of up to $100M per year Stock +2% after hoursMajor Estimate Revision • May 19Consensus revenue estimates increase by 11%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from US$966.8m to US$1.07b. Forecast losses expected to reduce from -US$1.16 to -US$1.02 per share. Healthcare Services industry in the US expected to see average net income growth of 19% next year. Consensus price target down from US$7.00 to US$4.75. Share price fell 4.1% to US$1.16 over the past week.Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.24 loss per share (down from US$0.04 loss in 1Q 2021). Revenue: US$266.4m (up 274% from 1Q 2021). Net loss: US$91.4m (loss widened US$80.9m from 1Q 2021). Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 24%. Over the next year, revenue is forecast to grow 113%, compared to a 17% growth forecast for the industry in the US.お知らせ • May 13Babylon Holdings Limited Revises Revenue Guidance for the Year 2022Babylon Holdings Limited revised revenue guidance for the year 2022. For the twelve months ending December 31, 2022, the Company is raising revenue guidance from the previous range of $900 million to $1 billion, to $1.0 billion or greater, based on higher than expected revenue attainment in first quarter 2022. This represents a more than 3x increase over 2021 revenue driven predominantly by organic growth, fueled by state expansion in the U.S. with existing clients, as well as members from new clients.Price Target Changed • Apr 27Price target decreased to US$7.30Down from US$8.30, the current price target is an average from 5 analysts. New target price is 437% above last closing price of US$1.36. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$1.15 next year compared to a net loss per share of US$1.36 last year.Board Change • Apr 27High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 1 experienced director. 1 highly experienced director. Founder, Chairman & CEO Parsa Parsadoust is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 13Babylon Holdings Limited to Report Q1, 2022 Results on May 12, 2022Babylon Holdings Limited announced that they will report Q1, 2022 results on May 12, 2022Major Estimate Revision • Mar 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$832.2m to US$970.3m. EPS estimate fell from -US$0.66 to -US$1.19 per share. Healthcare Services industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$11.20 to US$9.30. Share price fell 8.1% to US$4.79 over the past week.Reported Earnings • Mar 11Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$322.9m (up 307% from FY 2020). Net loss: US$368.5m (loss widened 97% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 164%, compared to a 19% growth forecast for the industry in the US.Breakeven Date Change • Mar 11No longer forecast to breakevenThe 5 analysts covering Babylon Holdings no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$39.6m in 2024. New consensus forecast suggests the company will make a loss of US$56.9m in 2024.お知らせ • Feb 16Babylon Holdings Limited to Report Q4, 2021 Results on Mar 10, 2022Babylon Holdings Limited announced that they will report Q4, 2021 results on Mar 10, 2022お知らせ • Feb 11Babylon Holdings Limited Announces Resignation of Stacy Saal as Chief Operating Officer, Effective February 12, 2022Stacy Saal, Chief Operating Officer of Babylon Holdings Limited has resigned effective February 12, 2022.Seeking Alpha • Jan 31Babylon Holdings: A Virtual Value-Based Care Leader With UpsideBabylon's growth outlook continues to improve as it builds on its existing capabilities with the acquisitions of DayToDay Health and Higi. In addition to its solid pipeline, Babylon should also benefit from a massive c. $10 trillion global opportunity, underpinning its longer-term growth runway. With shares trading at a wide discount to industry leader Teladoc, I see plenty of scope for upside ahead.お知らせ • Jan 20Babylon Holdings Limited (NYSE:BBLN) acquired DayToDay Health.Babylon Holdings Limited (NYSE:BBLN) acquired DayToDay Health on January 19, 2022. DayToDay’s team will join the Babylon team to lend their technical expertise, and to help merge DayToDay’s guiding mission to create the ultimate patient care experience for anybody, anywhere in the world, with Babylon’s mission to provide accessible and affordable healthcare care to every person on Earth. Babylon Holdings Limited (NYSE:BBLN) completed the acquisition of DayToDay Health on January 19, 2022.お知らせ • Jan 16+ 1 more updateBabylon Holdings Limited Increases Revenue Guidance for the Full-Year 2022Babylon Holdings Limited announced that the company is increasing full-year 2022 revenue guidance to be $900 million to $1 billion. This is an increase of up to 40% on previous revenue guidance of $710 million and represents approximately a tripling of the revenue expected for the 2021 fiscal year.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 4 analysts covering Babylon Holdings expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$45.0m in 2024. Average annual earnings growth of 35% is required to achieve expected profit on schedule.Board Change • Dec 31High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 1 experienced director. 1 highly experienced director. Founder, Chairman & CEO Parsa Parsadoust is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Dec 05Babylon Launches AI in Rwanda in Next Step Towards Digitising Healthcare in RwandaBabylon Holdings Limited has launched its AI-powered triage tool in Rwanda to further digitise the Rwandan healthcare system. Babylon, known locally as Babyl, has been delivering digital health services in Rwanda since 2016 and, last year, embarked on a 10-year partnership with the Government of Rwanda to build Africa’s first digital-first universal healthcare system. Babyl has over 2.6 million registered patients - and completes up to 4,000 consultations every day. Integrating Babylon’s cutting-edge technology, such as its AI-powered triage tool, into the existing Rwandan healthcare system is an important part of the company’s commitment to improving the quality and accessibility of healthcare across the country. The AI-powered triage tool is now being used by Babyl’s call center nurses to help them work more efficiently and make better, quicker decisions for their patients. The tool will help nurses ask patients the right questions, collect necessary information about a patient’s symptoms, and provide them with insights to help choose the correct triage path. If a follow-up appointment is needed, the patient information collected on the triage call is passed on to the doctor, saving both the clinician and the patient time. Babylon’s highly scalable technology platform has helped extend quality care to people all around the world, from hospitals in England’s NHS, to over 11 SE Asian countries through Babylon’s partnership with major insurer Prudential, to some of the most rural corners of America. The AI-backed triage tool now available to Babyl’s clinicians has been fully localised for Rwanda and accounts for local language, epidemiology, culture and health system pathways. Like many countries around the world, Rwanda struggles with issues of accessibility and affordability of healthcare, whilst also facing ever-rising levels of chronic disease and severe healthcare workforce shortages. The introduction of Babylon’s AI is a big step forward for Babylon’s commitment to support the Government of Rwanda’s agenda to digitally transform the national healthcare system.Reported Earnings • Nov 14Third quarter 2021 earnings released: US$0.08 loss per shareThe company reported a soft third quarter result with weaker control over costs, although losses were stable and revenues were flat. Third quarter 2021 results: Revenue: US$74.5m (flat on 3Q 2020). Net loss: US$65.2m (flat on 3Q 2020).株主還元BBLN.FUS Healthcare ServicesUS 市場7D22.2%-0.8%2.3%1Y-99.9%-44.4%25.5%株主還元を見る業界別リターン: BBLN.F過去 1 年間で-44.4 % の収益を上げたUS Healthcare Services業界を下回りました。リターン対市場: BBLN.Fは、過去 1 年間で25.5 % のリターンを上げたUS市場を下回りました。価格変動Is BBLN.F's price volatile compared to industry and market?BBLN.F volatilityBBLN.F Average Weekly Movement75.3%Healthcare Services Industry Average Movement10.0%Market Average Movement7.2%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.1%安定した株価: BBLN.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: BBLN.Fの 週次ボラティリティ は、過去 1 年間で40%から75%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト20131,895Parsa Parsadoustwww.babylonhealth.comもっと見るBabylon Holdings Limited 基礎のまとめBabylon Holdings の収益と売上を時価総額と比較するとどうか。BBLN.F 基礎統計学時価総額US$535.33k収益（TTM）-US$255.58m売上高(TTM)US$1.15b0.0xP/Sレシオ0.0xPER（株価収益率BBLN.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BBLN.F 損益計算書（TTM）収益US$1.15b売上原価US$1.15b売上総利益US$3.13mその他の費用US$258.71m収益-US$255.58m直近の収益報告Mar 31, 2023次回決算日該当なし一株当たり利益（EPS）-9.98グロス・マージン0.27%純利益率-22.14%有利子負債／自己資本比率-93.8%BBLN.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/08/09 18:52終値2023/08/09 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Babylon Holdings Limited これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Nisala WeerasuriyaBerenbergAllen LutzBofA Global ResearchRichard CloseCanaccord Genuity3 その他のアナリストを表示
お知らせ • Jun 29Babylon Announces the Receipt of Continued Listing Standards Notice from NYSE and Upcoming DelistingBabylon Holdings Limited announced that on June 22, 2023, the Company received a notice from the New York Stock Exchange indicating the Company is not in compliance with Section 802.01B and Section 802.01C of the NYSE Listed Company Manual because (i) the Company’s average total market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its last reported shareholders’ equity was less than $50 million, and (ii) the average closing price of the Company’s Class A ordinary shares on the NYSE was less than $1.00 over a consecutive 30 trading-day period. In light of the expected closing of the Proposed Transaction in July 2023, the Company does not intend to undertake actions to cure the deficiencies described above and return to compliance with the NYSE continued listing standards, and has notified the NYSE of this decision. As a result, the Company expects the NYSE to immediately suspend its Class A ordinary shares from trading on the NYSE under the ticker symbol “BBLN”, and for the Class A ordinary shares to transition to trading on the over-the-counter market. In addition, the Company expects the NYSE to subsequently delist the Class A ordinary shares from the NYSE in accordance with its procedures. The Company will continue to comply with applicable Securities and Exchange Commission reporting requirements. The Notice and the expected suspension of trading and subsequent delisting of the Class A ordinary shares from the NYSE do not affect the business operations of the Company and its subsidiaries, and will have no impact on the Proposed Transaction.
お知らせ • May 26Babylon Holdings Limited Announces Board ChangesOn May 24, 2023, Per Brilioth and Georgi Ganev notified the board of directors of Babylon Holdings Limited of their respective resignations as directors, effective immediately. The respective decisions of Messrs. Brilioth and Ganev were not the result of any dispute or disagreement with the Company on any matter relating to the Company’s operations, policies or practices. On May 19, 2023, the Board appointed Aidan de Brunner to the Board and the Audit, Nominating and Corporate Governance, Remuneration, and Strategic Committees of the Board, effective as of May 19, 2023. The Board has determined that Mr. de Brunner is independent under the standards of the Securities and Exchange Commission and the New York Stock Exchange, and meets the additional standards applicable to members of the Audit Committee. Mr. de Brunner was nominated by the Majority Bridge Noteholders pursuant to the bridge loan notes facility agreement, dated March 9, 2023, among the Company, as borrower, Babylon Healthcare Inc., Babylon Partners Ltd., Babylon Inc., and Babylon Group Holdings Limited, as guarantors, and Kroll Trustee Services Limited, as trustee and security agent, as amended and restated by the amendment and restatement agreement, dated May 10, 2023 (as so amended and restated, the "Amended Bridge Facility Agreement"). Mr. Eugene I. Davis, who was appointed to the Board effective as of March 30, 2023, and Mr. de Brunner are the two Bridge Noteholder-selected Independent Directors. If Mr. de Brunner resigns from the Board, the Majority Bridge Noteholders may nominate a replacement Bridge Noteholder-selected Independent Director, and the Company has agreed to use all reasonable endeavors to effect the appointment of such replacement Bridge Noteholder-selected Independent Director within the time period specified in the Amended Bridge Facility Agreement.
お知らせ • May 11Babylon Holdings Limited Announces Withdrawn Earnings Guidance for the Year 2023Babylon Holdings Limited announced withdrawn earnings guidance for the year 2023. In light of the company’s announcement concerning an interim financing and proposed take private transaction to be led by AlbaCore Capital LLP and affiliates, the company has withdrawn its full-year 2023 revenue guidance issued on March 9, 2023. The company is not providing updated guidance at this time.
Reported Earnings • May 11First quarter 2023 earnings released: US$2.53 loss per share (vs US$5.94 loss in 1Q 2022)First quarter 2023 results: US$2.53 loss per share (improved from US$5.94 loss in 1Q 2022). Revenue: US$311.1m (up 17% from 1Q 2022). Net loss: US$63.2m (loss narrowed 31% from 1Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in the US.
Recent Insider Transactions • Mar 22Global Chief Medical Officer recently sold US$74k worth of stockOn the 15th of March, Darshak Sanghavi sold around 10k shares on-market at roughly US$7.71 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Recent Insider Transactions • Mar 17Global Chief Medical Officer recently sold US$74k worth of stockOn the 15th of March, Darshak Sanghavi sold around 10k shares on-market at roughly US$7.74 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
お知らせ • Jun 29Babylon Announces the Receipt of Continued Listing Standards Notice from NYSE and Upcoming DelistingBabylon Holdings Limited announced that on June 22, 2023, the Company received a notice from the New York Stock Exchange indicating the Company is not in compliance with Section 802.01B and Section 802.01C of the NYSE Listed Company Manual because (i) the Company’s average total market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its last reported shareholders’ equity was less than $50 million, and (ii) the average closing price of the Company’s Class A ordinary shares on the NYSE was less than $1.00 over a consecutive 30 trading-day period. In light of the expected closing of the Proposed Transaction in July 2023, the Company does not intend to undertake actions to cure the deficiencies described above and return to compliance with the NYSE continued listing standards, and has notified the NYSE of this decision. As a result, the Company expects the NYSE to immediately suspend its Class A ordinary shares from trading on the NYSE under the ticker symbol “BBLN”, and for the Class A ordinary shares to transition to trading on the over-the-counter market. In addition, the Company expects the NYSE to subsequently delist the Class A ordinary shares from the NYSE in accordance with its procedures. The Company will continue to comply with applicable Securities and Exchange Commission reporting requirements. The Notice and the expected suspension of trading and subsequent delisting of the Class A ordinary shares from the NYSE do not affect the business operations of the Company and its subsidiaries, and will have no impact on the Proposed Transaction.
お知らせ • May 26Babylon Holdings Limited Announces Board ChangesOn May 24, 2023, Per Brilioth and Georgi Ganev notified the board of directors of Babylon Holdings Limited of their respective resignations as directors, effective immediately. The respective decisions of Messrs. Brilioth and Ganev were not the result of any dispute or disagreement with the Company on any matter relating to the Company’s operations, policies or practices. On May 19, 2023, the Board appointed Aidan de Brunner to the Board and the Audit, Nominating and Corporate Governance, Remuneration, and Strategic Committees of the Board, effective as of May 19, 2023. The Board has determined that Mr. de Brunner is independent under the standards of the Securities and Exchange Commission and the New York Stock Exchange, and meets the additional standards applicable to members of the Audit Committee. Mr. de Brunner was nominated by the Majority Bridge Noteholders pursuant to the bridge loan notes facility agreement, dated March 9, 2023, among the Company, as borrower, Babylon Healthcare Inc., Babylon Partners Ltd., Babylon Inc., and Babylon Group Holdings Limited, as guarantors, and Kroll Trustee Services Limited, as trustee and security agent, as amended and restated by the amendment and restatement agreement, dated May 10, 2023 (as so amended and restated, the "Amended Bridge Facility Agreement"). Mr. Eugene I. Davis, who was appointed to the Board effective as of March 30, 2023, and Mr. de Brunner are the two Bridge Noteholder-selected Independent Directors. If Mr. de Brunner resigns from the Board, the Majority Bridge Noteholders may nominate a replacement Bridge Noteholder-selected Independent Director, and the Company has agreed to use all reasonable endeavors to effect the appointment of such replacement Bridge Noteholder-selected Independent Director within the time period specified in the Amended Bridge Facility Agreement.
お知らせ • May 11Babylon Holdings Limited Announces Withdrawn Earnings Guidance for the Year 2023Babylon Holdings Limited announced withdrawn earnings guidance for the year 2023. In light of the company’s announcement concerning an interim financing and proposed take private transaction to be led by AlbaCore Capital LLP and affiliates, the company has withdrawn its full-year 2023 revenue guidance issued on March 9, 2023. The company is not providing updated guidance at this time.
Reported Earnings • May 11First quarter 2023 earnings released: US$2.53 loss per share (vs US$5.94 loss in 1Q 2022)First quarter 2023 results: US$2.53 loss per share (improved from US$5.94 loss in 1Q 2022). Revenue: US$311.1m (up 17% from 1Q 2022). Net loss: US$63.2m (loss narrowed 31% from 1Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in the US.
Recent Insider Transactions • Mar 22Global Chief Medical Officer recently sold US$74k worth of stockOn the 15th of March, Darshak Sanghavi sold around 10k shares on-market at roughly US$7.71 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Recent Insider Transactions • Mar 17Global Chief Medical Officer recently sold US$74k worth of stockOn the 15th of March, Darshak Sanghavi sold around 10k shares on-market at roughly US$7.74 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Major Estimate Revision • Mar 16Consensus revenue estimates decrease by 16%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$1.44b to US$1.21b. EPS estimate increased from -US$14.34 to -US$9.33 per share. Healthcare Services industry in the US expected to see average net income growth of 1.0% next year. Consensus price target down from US$16.25 to US$14.15. Share price fell 31% to US$6.86 over the past week.
Reported Earnings • Mar 10Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: US$8.91 loss per share (improved from US$33.95 loss in FY 2021). Revenue: US$1.11b (up 244% from FY 2021). Net loss: US$221.4m (loss narrowed 40% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 50%. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare Services industry in the US.
お知らせ • Feb 17Babylon Holdings Limited to Report Q4, 2022 Results on Mar 09, 2023Babylon Holdings Limited announced that they will report Q4, 2022 results on Mar 09, 2023
お知らせ • Jan 13Babylon Holdings Limited Provides Unaudited Earnings Guidance for the Year Ended December 31, 2022Babylon Holdings Limited provided unaudited earnings guidance for the year ended December 31, 2022. For the period, the company is expected to exceed $1.05 billion on both a U.S. GAAP and International Financial Reporting Standards (IFRS) basis, including revenue from the IPA business in California.
Major Estimate Revision • Nov 17Consensus estimates of losses per share improve by 10%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from US$1.08b to US$1.10b. EPS estimate increased from -US$1.13 per share to -US$1.01 per share. Healthcare Services industry in the US expected to see average net income growth of 12% next year. Consensus price target down from US$2.74 to US$2.10. Share price rose 17% to US$0.53 over the past week.
Price Target Changed • Nov 16Price target decreased to US$2.10Down from US$2.74, the current price target is an average from 7 analysts. New target price is 283% above last closing price of US$0.55. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$1.01 next year compared to a net loss per share of US$1.36 last year.
Board Change • Nov 16High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 1 experienced director. 1 highly experienced director. Founder, Chairman & CEO Parsa Parsadoust is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 11Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.23 loss per share (further deteriorated from US$0.08 loss in 3Q 2021). Revenue: US$288.9m (up 288% from 3Q 2021). Net loss: US$89.9m (loss widened 38% from 3Q 2021). Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 5.8%. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare Services industry in the US.
お知らせ • Nov 11+ 1 more updateVNV (Cyprus) Limited Engages in Discussions with Babylon Holdings LimitedOn November 10, 2022, VNV (Cyprus) Limited announced that it and its respective representatives have engaged and/or may engage, from time to time, in discussions with Babylon Holdings Limited’s management and/or board of directors, including any special committees of the Board, and/or their respective advisors, regarding, among other things, the Company’s business, strategies, management, governance, operations, personnel, performance, financial matters, capital structure, corporate expenses, status of projects, hedging, environmental, health and safety matters and strategic and other transactions, and have engaged and/or intend to, from time to time, engage in discussions with other current or prospective holders of Class A Shares and/or other equity, debt, notes, instruments or securities, or rights convertible into or exchangeable or exercisable for Class A Shares or such other equity, debt, notes, instruments or securities, of the Company industry analysts, research analysts, rating agencies, existing or potential strategic partners of the Company, acquirers or competitors, financial sponsors, investment firms, investment professionals, capital and potential capital sources, operators, financial, and other consultants and advisors and other third parties regarding such matters.
Seeking Alpha • Nov 09Babylon to execute 1-for-25 reverse share splitBabylon (NYSE:BBLN) is implementing a 1-for-25 reverse share split of its Class A ordinary shares in a bid to increase the per share trading price to regain compliance with NYSE's minimum share price requirement. The split will become effective on Dec 15, 2022 and the Class A ordinary shares will begin trading on a split-adjusted basis on Dec 16, 2022. Concurrent with the move, the par value of the Class A ordinary shares will be changed to $0.0001 per share. The number of issued and outstanding shares will be reduced from ~620M to ~24.8M shares.
お知らせ • Nov 05Babylon Holdings Limited announced that it has received $80 million in funding from VNV Global AB (publ), Kinnevik AB and other investorsOn November 3, 2022, Babylon Holdings Limited closed the transaction.
お知らせ • Oct 19Babylon Holdings Limited announced that it expects to receive $61.45 million in funding from VNV Global AB (publ), Kinnevik AB and other investorsBabylon Holdings Limited announced that it has agreed to sell an aggregate of 145,885,760 Class A ordinary shares at a price of $0.42122 per share for gross proceeds of $61,450,000 on October 17, 2022. The transaction will include participation from certain institutional, other accredited investors, and entities affiliated with returning investors VNV Global AB, Kinnevik AB. The closing of the PIPE is expected to occur on or about November 3, 2022. The securities to be sold in the PIPE are being offered in a transaction not involving a public offering, have not been registered under the Securities Act of 1933, as amended and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.
お知らせ • Oct 18Babylon Holdings Limited Announces Resignation of Yon Nuta as Chief Product Officer, Effective October 18, 2022Babylon Holdings Limited announced Yon Nuta has resigned from his position as chief product officer of the company, effective October 18, 2022. Mr. Nuta’s responsibilities are being transitioned to Aron England, the company’s Vice President of Product, who joined Babylon in August 2021 and leads the company’s product platform organization.
Seeking Alpha • Oct 17Babylon Holdings files to sell 145.89M Class A ordinary sharesBabylon (NYSE:BBLN) has agreed to sell an aggregate of 145.89M of its Class A ordinary shares to certain institutional and other accredited investors in a private investment in public equity at a price of $0.42122/share. Babylon anticipates that the gross proceeds from the Initial Subscriptions will be $61.45M, before deducting offering expenses payable by the Co. Babylon expects to use the proceeds from the PIPE to fund the ongoing development of its digital-first platform and services for managing population health, working capital and other general corporate purposes. The closing of the PIPE is expected to occur on or about November 3, 2022.
お知らせ • Oct 14Babylon Holdings Limited to Report Q3, 2022 Results on Nov 10, 2022Babylon Holdings Limited announced that they will report Q3, 2022 results on Nov 10, 2022
お知らせ • Oct 13Babylon Holdings Reportedly to Sell Meritage IPA Assets in Early 2023Babylon Holdings Limited (NYSE:BBLN) to sell Meritage IPA assets in early 2023 - Babylon intends to divest Meritage Medical Network. Proceeds from the sale are expected to provide sufficient capital for Babylon's funding requirements through profitability.
お知らせ • Sep 29Babylon Hires Andrew Hine as Vice President of the Europe, Middle East, & Africa & Asia Go-To-Market TeamBabylon announced the hiring of Andrew Hine as Vice President of the Go-to-Market team. Hine joins Babylon’s Go-to-Market leadership team from Ernst & Young. In this role, Hine will lead the company’s sales efforts in Asia and EMEA and he will work closely with Paul-Henri Ferrand, Babylon’s Chief Operating Officer (COO), to oversee the execution of Babylon’s overseas expansion. As Babylon continues to strengthen its capabilities and enhance its presence in new and existing markets, Hine will lead the company’s growing network of contracts, collaborations, and partnerships, as well as increase the scale of Babylon’s service delivery and offerings. Hine's extensive healthcare background spans 30 years, 13 of which were spent as an NHS Operational Manager and Trust Board Director. He has led service delivery at the frontline in tertiary and secondary acute care, primary care, and mental health care services. Following his tenure with the NHS, Hine joined KPMG where he established and led its UK healthcare business as a consulting partner for 13 years, leading client engagements across the UK, Europe and the Middle East, particularly focusing on the strategic design, operational improvement and leadership of health services, organizations and systems. After KPMG, Hine joined Ernst & Young as the company’s Head of Health for the Middle East and North Africa. He spent the last four years working extensively across Saudi Arabia, Qatar, and the United Arab Emirates.
お知らせ • Sep 23Babylon Receives Share Price Notice from the New York Stock Exchange Due to Non-Compliance with NYSE Rule 802.01CBabylon Holdings Limited announced that on September 15, 2022, it received notice from the New York Stock Exchange (the “NYSE”) that it is not in compliance with NYSE Rule 802.01C of the NYSE Listed Company Manual that requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period (the “Notice”). Babylon has notified the NYSE of its intent to cure this deficiency, within six months following the receipt of the Notice in accordance with the NYSE’s rules, by implementing a reverse share split. At Babylon’s Annual General Meeting of Shareholders on September 14, 2022, Babylon received shareholder approval of a reverse share split at a consolidation ratio of between 15 and 25. After Babylon’s Board of Directors approves the consolidation ratio to be applied, Babylon intends to move ahead with the implementation of the reverse share split as soon as possible in the fourth quarter of 2022. After effecting the reverse share split, the deficiency will be deemed cured if the closing price of the Class A ordinary shares promptly exceeds $1.00 per share, and the price remains above that level for at least the following 30 trading days.
Seeking Alpha • Sep 22Babylon receives NYSE notice and gets approval for reverse share split at a consolidation ratio of between 15 and 25Babylon (NYSE:BBLN) received notice from the NYSE that it is not in compliance with listings standards as it did not maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period. Company received shareholder approval of a reverse share split at a consolidation ratio of between 15 and 25, which is intended as soon as possible in Q4 2022. Company believes that a reverse share split will also benefit its shareholders because it will enable to reach additional institutional shareholders who impose minimum price requirements.
お知らせ • Aug 24Babylon Holdings Limited Announces Chief Financial Officer ChangesBabylon Holdings Limited announced that David Humphreys will be appointed as the Company’s new Chief Financial Officer. Mr. Humphreys has been at Babylon for nearly two years in the role of Finance Director, with overall responsibility for building and scaling Babylon’s finance function. Formerly, he was US-based as a Silicon Valley and New York Partner with PwC for over 20 years, working with Boards and leaders of fast-moving, rapid-growth companies including Tesla and Facebook to which he provided accounting consulting, transaction, IPO, M&A and auditing services to ensure compliance with PCAOB and SEC reporting requirements. During his time with PwC, Mr. Humphreys also served as a Practice Fellow at the International Accounting Standards Board, and is both a U.S. Certified Public Accountant (CPA) and an ICAEW Fellow Chartered Accountant. Current Chief Financial Officer, Charlie Steel, will leave his position to pursue another opportunity. Mr. Steel will remain at Babylon for a period to ensure the effective transition of his responsibilities to Mr. Humphreys.
Seeking Alpha • Aug 23Babylon gets new CFOBabylon (NYSE:BBLN) announces that David Humphreys will be appointed as new CFO. Mr. Humphreys has been at Babylon for nearly two years in the role of Finance Director, with overall responsibility for building and scaling company’s finance function. Current CFO, Charlie Steel, will leave his position to pursue another opportunity; Mr. Steel will remain at the compny for a period to ensure the effective transition of his responsibilities to Mr. Humphreys.
お知らせ • Aug 16Babylon Holdings Denies Acquisition RumorsBabylon Holdings Limited (NYSE:BBLN) announced that it is not engaged in nor has it had contact or discussions with any potential acquirer. The company is actively working with the staff of the NYSE to resume trading as soon as possible.
Seeking Alpha • Aug 15Babylon Holdings jumps after report of potential sale processBabylon Holdings (NYSE:BBLN) soared 9.2% after a report that the U.K.-based digital healthcare company is said to be consider a take private transaction. Babylon, which connects patients and doctors via an apps, is said to be holding early talks with investors about how to address its sinking share price, according to traders, who cited a Bloomberg report. BBLN shares have plunged 92% since going public through a SPAC transaction in October. The company is looking at options including a take private to a possible deal with a strategic partner, according to the report. Babylon (BBLN) could also look to raise new funds to grow its business. Babylon (BBLN) originally announced a deal to go public through SPAC Alkuri Global Acquisition in June of last year, which was expected to value the combined company at an equity value of about $4.2 billion. Babylon currently has a market value of about $287 million. Last Tuesday Babylon (BBLN) reported Q2 GAAP EPS of -$0.41, revenue of $265.36M.
Reported Earnings • Aug 11Second quarter 2022 earnings: EPS misses analyst expectationsSecond quarter 2022 results: US$0.41 loss per share (down from US$0.26 loss in 2Q 2021). Revenue: US$265.4m (up 362% from 2Q 2021). Net loss: US$157.1m (loss widened 144% from 2Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 54%. Over the next year, revenue is forecast to grow 81%, compared to a 19% growth forecast for the industry in the US.
お知らせ • Aug 10Babylon Holdings Limited Provides Guidance for the Twelve Months Ending December 31, 2022Babylon Holdings Limited providing guidance For the twelve months ending December 31, 2022, company is reiterating its revenue guidance of $1.0 billion or greater, which represents a more than 3x increase over 2021 revenue driven predominantly by organic growth, fueled by state expansion in the U.S. with existing clients, as well as members from new clients.
お知らせ • Aug 02Babylon Holdings Limited Announces Executive ChangesBabylon Holdings Limited announced that Paul-Henri Ferrand. Mr. Ferrand, formerly the Chief Business Officer of Babylon Holdings Limited (“Babylon”), has been appointed as Babylon’s Chief Operating Officer effective immediately. In this expanded role, Mr. Ferrand will continue to lead Babylon’s Go-to-Market teams, but will also lead Babylon’s wider business operations, including strategic and operational planning. Mr. Ferrand joined Babylon in October 2020. Prior to joining Babylon, Mr. Ferrand served as Chief Operating Officer at Brex, a financial services company, from November 2019 to September 2020. Previously, Mr. Ferrand served as President of Global Customer Operations at Google, from August 2017 to June 2019, and as Vice President US Sales & Operations at Google from May 2014 to August 2017. Steve Davis. Mr. Davis has resigned from his position as Chief Technology Officer, effective August 12, 2022. Mr. Davis’s responsibilities are being transitioned to Praveen Hirsave, Babylon’s Vice President of Engineering, who currently oversees Babylon’s member and artificial intelligence platform strategies. Babylon wishes Steve well in the future. Darshak Sanghavi. Effective immediately, Mr. Sanghavi’s role as Babylon’s Chief Medical Officer has been expanded to include oversight of Babylon’s clinical organizations. In this expanded role, Mr. Sanghavi’s additional responsibilities will include partnering with the regional general managers of Babylon’s clinical operations to ensure that Babylon’s technology and services create direct value to the improvement of contract margins and the engagement of Babylon’s members. Mr. Sanghavi joined Babylon in May 2021. Prior to joining Babylon, Mr. Sanghavi served as Chief Medical Officer at UnitedHealthcare, a provider of health benefits programs in the United States, from August 2019 to August 2020. Previously, Mr. Sanghavi served as Chief Medical Officer at OptumLabs, a pharmacy benefit manager and part of UnitedHealth Group Incorporated, from August 2016 to August 2019, and in the Obama Administration as the Director of Preventative and Population Health at the Center for Medicare and Medicaid Innovation from August 2014 to September 2016. Mr. Sanghavi is also an Associate Professor of Pediatrics and served as Chief of Pediatric Cardiology at the University of Massachusetts Medical School from October 2005 to August 2014.
お知らせ • Jul 29Babylon Holdings Limited, Annual General Meeting, Sep 14, 2022Babylon Holdings Limited, Annual General Meeting, Sep 14, 2022, at 09:00 Central Standard Time. Agenda: To consider Retirement and re-election of directors; To re-appoint KPMG LLP in the United Kingdom as auditors of the Company to hold office from the conclusion of the AGM ; to consider To approve the Reverse Share Split ; and to consider other matters.
お知らせ • Jul 13Babylon Holdings Limited to Report Q2, 2022 Results on Aug 09, 2022Babylon Holdings Limited announced that they will report Q2, 2022 results Pre-Market on Aug 09, 2022
お知らせ • Jul 07Babylon Holdings Limited Provides Earnings Guidance for the Year 2022Babylon Holdings Limited provided earnings guidance for the year 2022. For the year, the company expects there is no change to Babylon's revenue guidance being $1.0 billion or greater for Fiscal Year 2022.
Seeking Alpha • Jul 06Babylon +2%, expects $100M savings per yearBabylon (NYSE:BBLN) plans to accelerate its path to profitability through revenue and cost efficiencies, implemented in Q3 and expects effect in Q4. Company is improving its Adjusted EBITDA guidance for FY 2022 from $(295)M or less to $(270)M or less, with forecasted monthly December 2022. Adjusted EBITDA of $(18)M or less. No change to Babylon's revenue guidance being $1B or greater for FY 2022. Expects to generate savings of up to $100M per year Stock +2% after hours
Major Estimate Revision • May 19Consensus revenue estimates increase by 11%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from US$966.8m to US$1.07b. Forecast losses expected to reduce from -US$1.16 to -US$1.02 per share. Healthcare Services industry in the US expected to see average net income growth of 19% next year. Consensus price target down from US$7.00 to US$4.75. Share price fell 4.1% to US$1.16 over the past week.
Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.24 loss per share (down from US$0.04 loss in 1Q 2021). Revenue: US$266.4m (up 274% from 1Q 2021). Net loss: US$91.4m (loss widened US$80.9m from 1Q 2021). Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 24%. Over the next year, revenue is forecast to grow 113%, compared to a 17% growth forecast for the industry in the US.
お知らせ • May 13Babylon Holdings Limited Revises Revenue Guidance for the Year 2022Babylon Holdings Limited revised revenue guidance for the year 2022. For the twelve months ending December 31, 2022, the Company is raising revenue guidance from the previous range of $900 million to $1 billion, to $1.0 billion or greater, based on higher than expected revenue attainment in first quarter 2022. This represents a more than 3x increase over 2021 revenue driven predominantly by organic growth, fueled by state expansion in the U.S. with existing clients, as well as members from new clients.
Price Target Changed • Apr 27Price target decreased to US$7.30Down from US$8.30, the current price target is an average from 5 analysts. New target price is 437% above last closing price of US$1.36. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$1.15 next year compared to a net loss per share of US$1.36 last year.
Board Change • Apr 27High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 1 experienced director. 1 highly experienced director. Founder, Chairman & CEO Parsa Parsadoust is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 13Babylon Holdings Limited to Report Q1, 2022 Results on May 12, 2022Babylon Holdings Limited announced that they will report Q1, 2022 results on May 12, 2022
Major Estimate Revision • Mar 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$832.2m to US$970.3m. EPS estimate fell from -US$0.66 to -US$1.19 per share. Healthcare Services industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$11.20 to US$9.30. Share price fell 8.1% to US$4.79 over the past week.
Reported Earnings • Mar 11Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$322.9m (up 307% from FY 2020). Net loss: US$368.5m (loss widened 97% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 164%, compared to a 19% growth forecast for the industry in the US.
Breakeven Date Change • Mar 11No longer forecast to breakevenThe 5 analysts covering Babylon Holdings no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$39.6m in 2024. New consensus forecast suggests the company will make a loss of US$56.9m in 2024.
お知らせ • Feb 16Babylon Holdings Limited to Report Q4, 2021 Results on Mar 10, 2022Babylon Holdings Limited announced that they will report Q4, 2021 results on Mar 10, 2022
お知らせ • Feb 11Babylon Holdings Limited Announces Resignation of Stacy Saal as Chief Operating Officer, Effective February 12, 2022Stacy Saal, Chief Operating Officer of Babylon Holdings Limited has resigned effective February 12, 2022.
Seeking Alpha • Jan 31Babylon Holdings: A Virtual Value-Based Care Leader With UpsideBabylon's growth outlook continues to improve as it builds on its existing capabilities with the acquisitions of DayToDay Health and Higi. In addition to its solid pipeline, Babylon should also benefit from a massive c. $10 trillion global opportunity, underpinning its longer-term growth runway. With shares trading at a wide discount to industry leader Teladoc, I see plenty of scope for upside ahead.
お知らせ • Jan 20Babylon Holdings Limited (NYSE:BBLN) acquired DayToDay Health.Babylon Holdings Limited (NYSE:BBLN) acquired DayToDay Health on January 19, 2022. DayToDay’s team will join the Babylon team to lend their technical expertise, and to help merge DayToDay’s guiding mission to create the ultimate patient care experience for anybody, anywhere in the world, with Babylon’s mission to provide accessible and affordable healthcare care to every person on Earth. Babylon Holdings Limited (NYSE:BBLN) completed the acquisition of DayToDay Health on January 19, 2022.
お知らせ • Jan 16+ 1 more updateBabylon Holdings Limited Increases Revenue Guidance for the Full-Year 2022Babylon Holdings Limited announced that the company is increasing full-year 2022 revenue guidance to be $900 million to $1 billion. This is an increase of up to 40% on previous revenue guidance of $710 million and represents approximately a tripling of the revenue expected for the 2021 fiscal year.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 4 analysts covering Babylon Holdings expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$45.0m in 2024. Average annual earnings growth of 35% is required to achieve expected profit on schedule.
Board Change • Dec 31High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 1 experienced director. 1 highly experienced director. Founder, Chairman & CEO Parsa Parsadoust is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Dec 05Babylon Launches AI in Rwanda in Next Step Towards Digitising Healthcare in RwandaBabylon Holdings Limited has launched its AI-powered triage tool in Rwanda to further digitise the Rwandan healthcare system. Babylon, known locally as Babyl, has been delivering digital health services in Rwanda since 2016 and, last year, embarked on a 10-year partnership with the Government of Rwanda to build Africa’s first digital-first universal healthcare system. Babyl has over 2.6 million registered patients - and completes up to 4,000 consultations every day. Integrating Babylon’s cutting-edge technology, such as its AI-powered triage tool, into the existing Rwandan healthcare system is an important part of the company’s commitment to improving the quality and accessibility of healthcare across the country. The AI-powered triage tool is now being used by Babyl’s call center nurses to help them work more efficiently and make better, quicker decisions for their patients. The tool will help nurses ask patients the right questions, collect necessary information about a patient’s symptoms, and provide them with insights to help choose the correct triage path. If a follow-up appointment is needed, the patient information collected on the triage call is passed on to the doctor, saving both the clinician and the patient time. Babylon’s highly scalable technology platform has helped extend quality care to people all around the world, from hospitals in England’s NHS, to over 11 SE Asian countries through Babylon’s partnership with major insurer Prudential, to some of the most rural corners of America. The AI-backed triage tool now available to Babyl’s clinicians has been fully localised for Rwanda and accounts for local language, epidemiology, culture and health system pathways. Like many countries around the world, Rwanda struggles with issues of accessibility and affordability of healthcare, whilst also facing ever-rising levels of chronic disease and severe healthcare workforce shortages. The introduction of Babylon’s AI is a big step forward for Babylon’s commitment to support the Government of Rwanda’s agenda to digitally transform the national healthcare system.
Reported Earnings • Nov 14Third quarter 2021 earnings released: US$0.08 loss per shareThe company reported a soft third quarter result with weaker control over costs, although losses were stable and revenues were flat. Third quarter 2021 results: Revenue: US$74.5m (flat on 3Q 2020). Net loss: US$65.2m (flat on 3Q 2020).
